Starling Oncology (STLNW) Accounts Payables (2020 - 2026)

Starling Oncology (STLNW) has reported Accounts Payables for 7 consecutive years, with $60.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 72.56% year-over-year to $60.3 million; the trailing twelve-month figure through Jun 2026 stood at $60.3 million (up 72.56% YoY), and the FY2025 full-year result was $43.2 million, up 77.47% from the prior year.
• Accounts Payables rose to $60.3 million in Q2 2026 per STLNW's latest filing, from $47.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $60.3 million in Q2 2026 and bottomed at $9.4 million in Q4 2022.
• Historically, Accounts Payables has averaged $24.2 million across 5 years, with a median of $18.4 million in 2024.
• The widest YoY moves for Accounts Payables: up 50881.5% in 2022, down 39.76% in 2022.
• Over 5 years, Accounts Payables stood at $9.4 million in 2022, then jumped by 53.96% to $14.4 million in 2023, then surged by 68.58% to $24.3 million in 2024, then jumped by 77.47% to $43.2 million in 2025, then jumped by 39.64% to $60.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $60.3 million, $47.6 million, and $43.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.